Lara Sullivan, Pyxis Oncology CEO
May 24, 2023 07:35 AM EDTUpdated 08:48 AM
Deals

Small SPAC to tiny sale: Apex­i­gen sprints to Pyx­is On­col­o­gy in $16M ex­it

Kyle LaHucik

Senior Reporter

Pyx­is On­col­o­gy, the pub­lic Boston biotech breath­ing life in­to Pfiz­er’s an­ti­body-drug con­ju­gates plat­form, will buy Apex­i­gen, a small on­col­o­gy out­fit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times